Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

General Motors and Four Other Value Stocks Insiders Love

Insider purchases tend to be bullish signs for a company, and we like to look for factors which can narrow the universe of stocks bought by insiders further. One way to do so is to use the traditional value metric of a trailing price-to-earnings ratio to see how cheap a stock is relative to the company’s past performance. Using data from Fidelity and our own database of insider trades, here are five stocks which have low trailing P/E multiples and have seen at least one insider purchase in the last three months:

General Motors Company (NYSE:GM)

Two Board members at The Timken Company (NYSE:TKR) bought shares in the company at the end of July at prices of about $38 per share- slightly lower than the current stock price. Consensus insider buying is a particularly bullish sign for a stock (read more about consensus insider buying). Timken manufactures bearings and other machine tools that are sold to transportation customers, including the military. The company trades at 7 times earnings on both a trailing and a forward basis, and with revenue and earnings up last quarter compared to a year ago we’d be interested in looking at the company further.

For some time now Tractors and Farm Equipment Limited has been buying shares in AGCO Corporation (NYSE:AGCO); Tractors and Farm Equipment Limited is managed by AGCO Board member Mallika Srinivasan. The stock trades at 7 times trailing earnings, and is expected to grow substantially over the next few years due to higher agricultural demand. Its five-year PEG ratio is 0.8, reflecting that Wall Street analysts consider it a buy given its value and growth characteristics. We think AGCO deserves consideration among other potential investments with exposure to agriculture.

Multiple insiders have also been buying at CNO Financial Group Inc (NYSE:CNO), a $2.3 billion market cap health and life insurance company (research insider activity at CNO Financial). CNO carries a trailing P/E multiple of 7, but analysts are skeptical that its strong performance (earnings were up 30% in the second quarter compared to the same period in 2011) will continue and their estimates imply a considerably higher forward P/E, at 12. CNO is also highly exposed to the broader market with a beta of 2.2. The consensus insider buy is interesting but we don’t see a reason to choose it over Timken of AGCO.

Axis Capital Holdings Limited (NYSE:AXS), a property and casualty insurer, saw its new CEO John Nichols invest over $1 million in the stock in late August. Axis’s stock is up 38% since a year ago, which has tracked a strong increase in earnings despite revenue being essentially flat. Axis’s $4.7 billion market capitalization places it at 8 times trailing earnings, but as with CNO the Street is pessimistic for 2013 and its consensus of $3.80 in earnings per share next year- down from an expectation of $3.98 in 2012- place it at a valuation of 10 times forward estimates. It actually seems like a more interesting insurer to research than CNO.

Finally, General Motors Company (NYSE:GM) CEO Dan Akerson bought 25,000 shares of the stock in August (though this was at an average price of $20.35, and the share price has risen about 20% since then). GM, at trailing and forward P/Es of 9 and 6, respectively, certainly qualifies as a value stock and billionaire David Einhorn of Greenlight Capital recommended buying it at the Value Investing Congress earlier this month. Read our analysis of GM. We were a bit skeptical of his pick, as European and international operations remain weak and the U.S. hasn’t been strong enough to carry its earnings higher (particularly given its declining market share). As a result we wouldn’t want to be long GM either.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!